(Total Views: 517)
Posted On: 08/24/2025 1:44:29 AM
Post# of 158106
CytoDyn conducted a Phase II "basket trial" (NCT04504942) for its drug leronlimab (a CCR5 antagonist) across 22 cancer types, with glioblastoma (GBM) showing a 9-point increase in Partial Tumor Size Reduction (PTSR) after the trial's completion in November 2021.
** Results for Glioblastoma: The trial saw a significant increase in the Partial Tumor Size Reduction (PTSR) for GBM, rising by 9 points to 32%.
___
Trial was 525mg & did not include PD-L1 / ICI.
** Results for Glioblastoma: The trial saw a significant increase in the Partial Tumor Size Reduction (PTSR) for GBM, rising by 9 points to 32%.
___
Trial was 525mg & did not include PD-L1 / ICI.
(8)
(0)
